# A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma

> **NCT03091257** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03091257
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-21
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-09-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091257, "A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03091257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*